IQVIA Holdings (NYSE:IQV) agreed to acquire discovery services assets from Charles River Laboratories. The deal focuses on in ...

A team of UC Santa Barbara engineering and molecular biology graduate students has developed software to accelerate the discovery process for therapies ...

French preclinical CRO NovAliX has found a new partner across the pond. Massachusetts-based manufacturer Bruker Corporation has announced a minority investment in the CRO. “This partnership with ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Figure 1. This figure depicts the four categories of protein druggability target screening tools discussed in this section, which include structure-based methods, sequence-based methods, machine ...

The MarketWatch News Department was not involved in the creation of this content. Advancing proprietary AI discovery of high-bioavailability Oral GLP-1 drug candidates. HOUSTON, Feb. 3, 2026 ...

Overview: The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the ...

Isomorphic Lab’s proprietary drug-discovery model is a major advance, but scientists developing open-source tools are left ...

In drug discovery, virtual screening is a fast and cost-effective way of narrowing down vast chemical libraries to identify the most promising hits, reducing synthesis and testing requirements while ...

This article is based on a poster originally authored by Daniel A. Barr, Mario Öeren, Peter A. Hunt, Jonathan D. Tyzack, Tomáš Chrien, Tamsin E. Mansley and Matthew D. Segall, which was presented at ...

Advancing proprietary AI discovery of high-bioavailability Oral GLP-1 drug candidates. HOUSTON, Feb. 3, 2026 /PRNewswire/ -- Deep EigenMatics, Inc., a pioneer in high-velocity Artificial Intelligence ...